Provided by Tiger Trade Technology Pte. Ltd.

KraneShares MSCI All China Health Care Index ETF

17.84
-0.1300-0.72%
Volume:33.44K
Turnover:596.90K
Market Cap:105.26M
PE:- -
High:18.01
Open:17.97
Low:17.75
Close:17.97
52wk High:21.50
52wk Low:14.38
Shares:5.90M
Float Shares:5.90M
Volume Ratio:0.64
T/O Rate:0.57%
Dividend:0.71
Dividend Rate:4.01%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Loose Fed Bets and AI Monetization Fuel Hong Kong Stocks Rally

Stock News
·
Sep 04

WuXi Bio Issues 3.2 Million Shares Following Option Exercise

Stock News
·
Sep 04

Wall Street Cues, Easing Bond Yields Boost Asian Stock Markets

MT Newswires Live
·
Sep 04

Daiwa Highlights AKESO's HARMONi-2 Milestone, Bolstering Case for Global NSCLC Study Success

Stock News
·
Sep 04

Brokerage Adds Tencent and Innovent Bio to Buy List While Maintaining Positive Outlook on Tech and Hardware Sectors

Stock News
·
Sep 04

WuXi Biologics Files HKEX Next-Day Disclosure Return, Share Capital Rises by 2,423,900 Shares

Reuters
·
Sep 03

Wuxi Biologics (Cayman) Stock Advances 3.0% in Hong Kong

Dow Jones
·
Sep 03

CSPC Pharmaceutical Group Stock Climbs 4.8% in Hong Kong

Dow Jones
·
Sep 03

Clinical Data Readouts Take Center Stage as Chinese Biotech Firms Surge; CSPC Pharma Climbs Over 4% While Huabao's HK Biotech ETF Holds Key Support

Deep News
·
Sep 03

Akeso - Ivonescimab Meets Os Key Secondary Endpoint in Harmoni-2 Study

THOMSON REUTERS
·
Sep 03

Akeso Says Ivonescimab Meets Overall Survival Endpoint in Phase III HARMONi-2 Lung Cancer Trial

Reuters
·
Sep 03

Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase Iii Harmoni-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line Pd-L1-Positive Nsclc

THOMSON REUTERS
·
Sep 03

Akeso - Ivonescimab Demonstrates Statistically Significant Improvement over Pembrolizumab

THOMSON REUTERS
·
Sep 03

WuXi Biologics Files HKEX Next-Day Disclosure Return Reporting 1,527,500 New Shares Issued Via Option Exercises

Reuters
·
Sep 02

CSPC Pharmaceutical Initiates Phase I Clinical Trial of Syh2056 Tablets in China

Reuters
·
Sep 01

Innovent Biologics Grants 583,731 Restricted Shares Under 2024 Share Scheme

Reuters
·
Sep 01

Innovent Biologics Files List of Board, Board Committee Members with Disclosure Duties

Reuters
·
Sep 01

CSPC Pharma's SYS6010 Gets Breakthrough Therapy Designation for New Indication in China

MT Newswires Live
·
Sep 01

CSPC Pharma Initiates Depression Drug Candidate Trial in China

MT Newswires Live
·
Sep 01

CSPC Pharmaceutical - Sys6010 Granted Breakthrough Therapy Designation by Nmpa in China for R/M Hnscc

THOMSON REUTERS
·
Sep 01